Breakthrough Glioblastoma Treatments Move Closer to Patients as Medicines Discovery Catapult and King’s College London Secure Brain Tumour Charity Funding
The collaborative project aims to accelerate a new approach to treat the most aggressive forms of brain cancer
Medicines Discovery Catapult (MDC) and King’s College London (KCL) have been awarded £400k funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.
Glioblastomas are the most common form of brain cancer and are highly aggressive, with poor survival outcomes. Patients survive on average for just 12-18 months after diagnosis, with only one-third of patients surviving for a year or more. Despite decades of intensive research and a greater understanding of glioblastoma tumour biology, there are still limited effective treatment options.
Spearheaded by KCL and MDC, the project will bring together proprietary technologies to offer a new route to deliver drugs safely and effectively into brain tumours.
Claire Kavanagh’s 19-year-old son, Niall, died in 2021, just three weeks after he was diagnosed with glioblastoma. Claire passionately supports and advocates for efforts like this that bring scientific breakthroughs closer to those who urgently need them, driven by her devastating and unexpected loss.
